LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Bristol-Myers Squibb Co.

Fechado

SetorSaúde

46.75 2.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

45.73

Máximo

46.79

Indicadores-chave

By Trading Economics

Rendimento

2.4B

2.5B

Vendas

-1.1B

11B

P/E

Médio do Setor

17.384

56.602

EPS

1.8

Rendimento de Dividendos

5.15

Margem de lucro

21.98

Funcionários

34,100

EBITDA

1.9B

4.5B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+22.79% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

5.15%

2.45%

Próximos Ganhos

31 de jul. de 2025

Próxima data de dividendos

31 de jul. de 2025

Próxima data de ex-dividendo

4 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-17B

95B

Abertura anterior

44.5

Fecho anterior

46.75

Sentimento de Notícias

By Acuity

45%

55%

157 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Bristol-Myers Squibb Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 11:32 UTC

Ganhos

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

13 de mai. de 2025, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12 de mai. de 2025, 22:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 de mai. de 2025, 18:45 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 de mai. de 2025, 17:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 de mai. de 2025, 12:07 UTC

Conversa de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7 de mai. de 2025, 20:09 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio 1Q Rev $22.9M >TSVT

7 de mai. de 2025, 20:08 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio 1Q EPS 1c >TSVT

7 de mai. de 2025, 20:08 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio: Tender Offer Related to Bristol Myers Squibb Deal to Expire May 12 Unless Extended

7 de mai. de 2025, 20:07 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio: HSR Waiting Period Expired for Sale to Bristol Myers Squibb

29 de abr. de 2025, 19:47 UTC

Ganhos

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 de abr. de 2025, 15:22 UTC

Ganhos

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 de abr. de 2025, 11:46 UTC

Ganhos

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 de abr. de 2025, 11:42 UTC

Ganhos

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 de abr. de 2025, 11:12 UTC

Ganhos

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

28 de abr. de 2025, 21:15 UTC

Ganhos

Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 14:15 UTC

Principais Notícias
Ganhos

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 12:37 UTC

Conversa de Mercado
Ganhos

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 de abr. de 2025, 11:17 UTC

Ganhos

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 de abr. de 2025, 11:13 UTC

Principais Notícias
Ganhos

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 de abr. de 2025, 10:59 UTC

Ganhos

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

Comparação entre Pares

Variação de preço

Bristol-Myers Squibb Co. Previsão

Preço-alvo

By TipRanks

22.79% parte superior

Previsão para 12 meses

Média 56.25 USD  22.79%

Máximo 68 USD

Mínimo 36 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

20 ratings

5

Comprar

14

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 50.57Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

157 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.